Optimising patient recall of adverse events over prolonged time periods by Hiller, Louise et al.
POSTER PRESENTATION Open Access
Optimising patient recall of adverse events over
prolonged time periods
Louise Hiller
1*, Janet A Dunn
1, Helen B Higgins
1, Emma Ogburn-Storey
1, Shrushma Loi
1, Anne-Laure Vallier
2,
Helena M Earl
3
From Clinical Trials Methodology Conference 2011
Bristol, UK. 4-5 October 2011
Objectives
Large, simple, pragmatic, low-risk, maintenance treat-
ment trials may seem straightforward to design, run and
analyse. However, if trial case record forms (CRFs) are
completed infrequently, the reliability of patient recall
over these long time-periods is questionable, especially
when recording individual incidences and severity of
toxicities of specific interest to the trial. It is essential to
know these detailed toxicities as it forms an indication
of the reduced level of exposure when comparing treat-
ment duration in a non-inferiority trial. Optimal meth-
ods of achieving accurate data are required.
Methods
PERSEPHONE is an investigator-led phase III trial of
trastuzumab treatment duration where patients on each
trial arm are treated every 21 days for either 9 or 18
cycles of treatment. Treatments are administered in che-
motherapy outpatient departments or at the patient’s
home via Healthcare at Home Ltd. PERSEPHONE
CRFs, which include all adverse events of interest, are
completed by the site research team at the 3-monthly
clinic visits where PERSEPHONE patients are routinely
followed up for the first year following start of trastuzu-
mab treatment.
To optimise reporting, the PERSEPHONE team have
developed Patient Diary Sheets which list the common
expected toxicities. For each trastuzumab cycle, patients
are requested to record how much they are ‘troubled by
each of the possible side-effects’ using patient-friendly
severity ratings (0=Not at all, 1=A little, 2=Moderate,
3=Quite a bit, 4=Very much).
Results
To date 1260 patients have been recruited into the PER-
SEPHONE trial with adverse event information sum-
marised on over 10,000 trastuzumab doses. At the 3-
m o n t h l yc l i n i cv i s i t s ,t h es i t er e s e a r c ht e a md i s c u s st h e
detailed patient diary information with the patient and
accurately interpret the information into incidences of
toxicities and relevant Common Terminology Criteria
for Adverse Events (CTCAE) grades for entry onto the
trial CRFs. The patient diaries are not entered onto the
database for analysis as they are used solely as memory
aids.
Conclusions
Feedback from the clinical research teams at sites indi-
cates that the method adopted in the PERSEPHONE
trial appears to work well. The Patient Diary Sheet is
indeed well received and utilised by the patients and
reported as a very useful memory aid at clinic visits.
Whilst it may seem counterintuitive to ask for additional
data which will never be scrutinised by the PERSE-
PHONE trial team, the strength of the final data col-
lected has been optimised by the use of these data
triggers.
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